Tempus AI secures $200 million five-year commitment from AstraZeneca

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Tempus AI signed a contract amendment with AstraZeneca on November 16, 2026, securing a $200 million, five-year spending commitment. * The renewal takes effect January 1, 2027, extending the master services agreement through December 31, 2031. * AstraZeneca targets annual spending of $40 million across products and services, with a $32 million minimum each calendar year. * An unmet aggregate commitment would extend the renewal through December 31, 2032, to address the shortfall. * AstraZeneca retains termination rights but must pay any shortfall against its $200 million commitment if it terminates for convenience. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-466240), on November 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.